Type 2 DiabetesPhase 1NCT07691177
Bioequivalence Study to Compare Imeglimin HCl 500 mg Film Coated Tablets Versus Twymeeg Tablets 500 mg
A Phase 1 study testing Imeglimin Hydrochloride Film Coated Tablet and TWYMEEG® Tablets in people with Type 2 Diabetes, run by Humanis Saglık Anonim Sirketi at 1 site in India.
Trial summary
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Read more about this study
- Who is it for?
- Ages 18 to 45 yearsHealthy volunteers can take part
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Imeglimin Hydrochloride Film Coated Tablet and TWYMEEG® Tablets
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 40 participants
- Where
- 1 siteIndia
- Study dates
- 6 Feb 2026to 13 May 2026
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 45 years
- All sexes
- Healthy volunteers accepted
- Adult
Who may be able to join
- Participants aged between 18 to 45 years (both inclusive).
- Participants' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
- Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- Participants having clinically acceptable 12-lead electrocardiogram (ECG).
- Participants having clinically acceptable chest X-Ray (PA view), if taken.
- Participants having negative urine screen for drugs of abuse (including amphetamines, barbiturates, benzodiazepines, marijuana, cocaine and morphine).
Show all 15Show fewer
- Participants having negative urine alcohol test / breath alcohol test.
- Non-smoker.
- Participants willing to adhere to the protocol requirements and to provide written informed consent.
- For male Participants:
- 1-Participants willing to follow approved birth control methods (a double barrier method) for the duration of the study as judged by the investigator(s), such as (a double barrier method) condom with spermicide, Condom with diaphragm, or abstinence. Participants willing to refrain from donating sperm during the study period
- For Female Participants:
- Female of child bearing potential practicing an acceptable method of birth control for the duration of the study as judged by the investigator(s), such as intrauterine device (IUD), abstinence, bilateral tubal ligation or double barrier contraception, i.e., condom + diaphragm, condom + spermicidal or foam
- Postmenopausal for at least 1 year, or if less than 1 year, then following acceptable contraceptive measures as mentioned above
- Participants having negative urine pregnancy test at screening and negative serum ƒÒ-hCG pregnancy test on admission day of period 01 (only for female Participants).
Who cannot join
- Hypersensitivity to Imeglimin or related class of drugs or any of its excipients or heparin.
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
- Presence of alcoholism or drug abuse.
- History or presence of asthma, urticaria or other significant allergic reactions.
- History or presence of significant gastric and/or duodenal ulceration.
Show all 20Show fewer
- History or presence of significant thyroid disease, adrenal dysfunction, organic intracranial lesion such as pituitary tumor.
- History or presence of cancer or basal or squamous cell carcinoma.
- Difficulty with donating blood.
- Difficulty in swallowing solids dosage form like tablets or capsules.
- Use of any prescribed medication or OTC medication including vaccines, vitamins and herbal remedies during last 30 days prior to admission in period 01.
- Major illness within past 3 months.
- Participant who have donated blood (1 unit) or participation in a drug research study within past 90 days prior to the first dose of the study drug.
- Consumption of xanthine-containing products, tobacco containing products or alcohol or any alcohol containing products within 48.00 hours prior to admission in period 01.
- Consumption of grapefruit or grapefruit juice containing products within 72.00 hours prior to admission of period 01.
- Positive screening test for any one or more: HIV, Hepatitis B and Hepatitis C.
- History or presence of significant easy bruising or bleeding.
- History or presence of significant recent trauma.
- Participants who have been on an abnormal diet (for whatever reason) during the four weeks preceding the study.
- Female Participants who are currently breast feeding.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets and Twymeeg Tablets 500 mg in Healthy, Adult, Human Participants Under Fasting Condition.
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Twymeeg Tablets 500 mg of Sumitomo Pharma Co., Ltd. 2-6-8, Dosho-machi, Chuo-Ward, Osaka City, in Healthy, Adult, Human Participants Under Fasting Condition.
- Conditions
- Type 2 Diabetes
- Being tested
- Imeglimin Hydrochloride Film Coated Tablet, TWYMEEG® Tablets
- Medical subject headings
- Diabetes Mellitus, Type 2
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Imeglimin Hydrochloride Film Coated TabletDrug
1 tablet of 500 mg Imeglimin Hydrochloride
TWYMEEG® TabletsDrug
1 tablet of 500 mg Imeglimin Hydrochloride
| Study group | Role | What they receive |
|---|---|---|
| Imeglimin Hydrochloride Film Coated Tablet | Experimental | Imeglimin Hydrochloride 500 mg Film Coated Tablet Receives: Drug: Imeglimin Hydrochloride Film Coated Tablet; Drug: TWYMEEG® Tablets |
| TWYMEEG® Tablets | Active comparator | TWYMEEG® Tablets (500 mg Imeglimin Hydrochloride) Receives: Drug: Imeglimin Hydrochloride Film Coated Tablet; Drug: TWYMEEG® Tablets |
What is being measured
The primary outcome is the main question the study is designed to answer.
Peak Plasma Concentration (Cmax)
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for Cmax.
Measured: 72.00 hours
Area Under the Curve from time zero to time of last measurable concentration (AUC0-t)
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for AUC0-t.
Measured: 72.00 hour
Secondary outcomes (5)
Area Under the Curve from time zero to time infinite (AUC0-∞)
Descriptive Statistic
Measured: 72.00 hour
Time to reach peak plasma concentration (Tmax)
Descriptive Statistic
Measured: 72.00 hours
Plasma Elimination Half-Life (t1/2)
Descriptive Statistic
Measured: 72.00 hours
Kel
Descriptive Statistic
Measured: 72.00 hours
AUC0-t/ AUC0-∞
Descriptive Statistic
Measured: 72 hours
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted8 Jul 2026
- Study start6 Feb 2026
- Primary completion27 Mar 2026
- Study completion13 May 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Humanis Saglık Anonim Sirketi
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07691177
- Sponsor's protocol ID
- 25-VIN-0596
- Status last verified
- Jul 2026
- First submitted
- 1 Jul 2026
- Last updated
- 8 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 8 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- An Open Label, Balanced, Randomized, Single Dose, Two Treatment, Two Sequence, Two Period, Two Way Crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets and Twymeeg Tablets 500 mg in Healthy, Adult, Human Participants Under Fasting Condition.
- ClinicalTrials.gov ID
- NCT07691177
- Acronym / sponsor ID
- 25-VIN-0596
- Conditions
- Type 2 Diabetes
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Humanis Saglık Anonim SirketiIndustry (pharma, biotech, devices)
- Study start
- 6 Feb 2026 (actual)
- Primary completion
- 27 Mar 2026 (actual)
- Study completion
- 13 May 2026 (actual)
- First posted
- 8 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
An Open Label, Balanced, Randomized, Single dose, Two treatment, Two sequence, Two period, Two way crossover, Oral Bioequivalence Study of Imeglimin HCl 500 mg Film Coated Tablets of Humanis Sağlık A.Ş., Ç.O.S.B. Karaağaç Mahallesi Fatih Bulvarı No:32 Kapaklı/TEKİRDAĞ and Twymeeg Tablets 500 mg of Sumitomo Pharma Co., Ltd. 2-6-8, Dosho-machi, Chuo-Ward, Osaka City, in Healthy, Adult, Human Participants Under Fasting Condition.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Imeglimin Hydrochloride Film Coated Tablet | Experimental | Drug: Imeglimin Hydrochloride Film Coated Tablet, Drug: TWYMEEG® TabletsImeglimin Hydrochloride 500 mg Film Coated Tablet |
| TWYMEEG® Tablets | Active comparator | Drug: Imeglimin Hydrochloride Film Coated Tablet, Drug: TWYMEEG® TabletsTWYMEEG® Tablets (500 mg Imeglimin Hydrochloride) |
Who may qualify
- Ages
- 18 to 45 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (15 listed)
- Participants aged between 18 to 45 years (both inclusive).
- Participants' weight within normal range according to normal values for Body Mass Index (between 18.5 to 30.0 kg/m2) (both inclusive) with minimum of 45 kg weight.
- Participants with normal health as determined by personal medical history, clinical examination and laboratory examinations within Predefined site Normal range [Annexure III].
- Participants having clinically acceptable 12-lead electrocardiogram (ECG).
- Participants having clinically acceptable chest X-Ray (PA view), if taken.
Key exclusion criteria (20 listed)
- Hypersensitivity to Imeglimin or related class of drugs or any of its excipients or heparin.
- History or presence of significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, endocrine, immunological, dermatological, neurological, urogenital or psychiatric disease or disorder.
- Any treatment which could bring about induction or inhibition of hepatic microsomal enzyme system within 30 days prior to admission in period 01.
- Presence of alcoholism or drug abuse.
- History or presence of asthma, urticaria or other significant allergic reactions.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Imeglimin Hydrochloride Film Coated Tablet1 tablet of 500 mg Imeglimin Hydrochloride | Drug | Imeglimin Hydrochloride Film Coated Tablet, TWYMEEG® Tablets |
| TWYMEEG® Tablets1 tablet of 500 mg Imeglimin Hydrochloride | Drug | Imeglimin Hydrochloride Film Coated Tablet, TWYMEEG® Tablets |
Primary outcome
Peak Plasma Concentration (Cmax)
Time frame: 72.00 hours
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for Cmax.
Area Under the Curve from time zero to time of last measurable concentration (AUC0-t)
Time frame: 72.00 hour
Acceptance range for bioequivalence was 80.00%-125.00% for 90% confidence intervals for the geometric least square mean ratio for AUC0-t.
5 secondary outcomes
Area Under the Curve from time zero to time infinite (AUC0-∞)
Time frame: 72.00 hour
Time to reach peak plasma concentration (Tmax)
Time frame: 72.00 hours
Plasma Elimination Half-Life (t1/2)
Time frame: 72.00 hours
Kel
Time frame: 72.00 hours
AUC0-t/ AUC0-∞
Time frame: 72 hours
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 8 Jul 2026.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing Imeglimin Hydrochloride Film Coated Tablet and TWYMEEG® Tablets in people with Type 2 Diabetes, run by Humanis Saglık Anonim Sirketi at 1 site in India.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 15 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 8 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in India. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Peak Plasma Concentration (Cmax) (time frame: 72.00 hours). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 8 Jul 2026.